Earnings (Loss) Per Common Share (Tables)

9 Months Ended

Sep. 30, 2021

Computation of basic and diluted earnings per share

The following table sets forth the computation of basic and diluted earnings per share available for common stockholders for the three and nine months ended September 30, 2021 and 2020 (in thousands, except per share data):


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021		2020
Income (loss) from continuing operations	$	(13,040)	$	(37,035)	$	(33,337)	$	(317,535)
Income (loss) from discontinued operations, net of tax	—		(1,135)		1,383		(2,908)
Net income (loss)	(13,040)		(38,170)		(31,954)		(320,443)
Less:
Net loss attributable to non-controlling interests	—		(822)		—		(822)
Net income (loss) available for common shareholders - basic and diluted	$	(13,040)	$	(37,348)	$	(31,954)	$	(319,621)

Weighted-average common shares outstanding - basic and diluted	85,800		85,172		85,306		82,615

Income (loss) per common share
Basic and diluted
Continuing operations	$	(0.15)	$	(0.43)	$	(0.39)	$	(3.84)
Discontinued operations	—		(0.01)		0.02		(0.03)
Basic and diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.	$	(0.15)	$	(0.44)	$	(0.37)	$	(3.87)

Schedule of antidilutive securities excluded from computation of earnings per share

Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above for the three and nine months ended September 30, 2021 and 2020 are presented below:


	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2021	2020	2021	2020
Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")	2,012	1,042	1,700	600
Stock options	2,004	1,362	2,008	1,016
Convertible senior notes	12,696	9,789	12,696	10,169
Total	16,712	12,193	16,404	11,785